[ad_1]
The Russian Federal Biomedical Agency has announced that the drug “Covid globulin”, the world’s first registered immune drug, is currently in clinical trials.
“The first phase of clinical trials of a drug prepared in the laboratory of Rostec Immunocompany Natsembio, which is a unique anti-Covid immunoglobulin is underway,” said Olga Eichler, head of the medical support department at the Federal Agency biomedical medicine from Russia, in a press release. a statement on the sidelines of the Eastern Economic Forum, according to Russian media.
expressive
In early April, the Russian Ministry of Health registered the world’s first separate immunoglobulin for the Corona virus, based on the blood plasma of people recovering from the disease.
After the completion of the second and third phases of clinical trials, the drug is expected to be used in the treatment of moderate and severe cases of Covid-19 infection.
The Corona virus has killed at least 4,565,622 people worldwide since the World Health Organization’s office in China reported the outbreak of the disease in late December 2019.
At least 220,652,860 people have been confirmed to have contracted the virus since its onset. The vast majority of those infected have recovered, although some continued to show symptoms weeks or even months later.
The figures are based on daily reports published by the health authorities in each country and exclude subsequent reviews by statistical agencies which indicate a much higher number of deaths.
The World Health Organization, given the excess mortality directly or indirectly linked to Covid-19, considers that the outcome of the epidemic could be two or three times greater than the officially announced outcome.
Source link
